Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7.

The aim of the present study was to determine the effect of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and adriamycin (ADM) on the human breast cancer cell line MCF-7 and to identify potential mechanisms of apoptosis. Cell viability was analyzed by the MTT assay and the synergistic effect was assessed by the Webb coefficient. Apoptosis was quantified using the annexin V-FITC and propidium iodide staining flow cytometry. The mRNA expression of TRAIL receptors was measured by RT-PCR. Changes in the quantities of Bax and caspase-9 proteins were determined by Western blot. MCF-7 cells were relatively resistant to TRAIL (IC50 >10 microg/mL), while MCF-7 cells were sensitive to ADM (IC50 <10 microg/mL). A subtoxic concentration of ADM (0.5 microg/mL) combined with 0.1, 1, or 10 microg/mL TRAIL had a synergistic cytotoxic effect on MCF-7 cells, which was more marked with the combination of TRAIL (0.1 microg/mL) and ADM (0.5 microg/mL). In addition, the combined treatment with TRAIL and ADM significantly increased cell apoptosis from 9.8% (TRAIL) or 17% (ADM) to 38.7%, resulting in a synergistic apoptotic effect, which is proposed to be mediated by up-regulation of DR4 and DR5 mRNA expression and increased expression of Bax and caspase-9 proteins. These results suggest that the combination of TRAIL and ADM might be a promising therapy for breast cancer.

[1]  S. Anderson,et al.  Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL , 2000, Molecular and Cellular Biology.

[2]  M. Fukushima,et al.  Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. , 2002, European journal of cancer.

[3]  E. Dirice,et al.  High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients , 2009, Pancreas.

[4]  S. Wang,et al.  The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway , 2008, Oncogene.

[5]  Y. Kakehi,et al.  Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. , 2007, The Journal of urology.

[6]  W. Winkelmann,et al.  Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells , 2003, International journal of cancer.

[7]  F. Khuri,et al.  p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site , 2004, Cancer Research.

[8]  S. Gibson,et al.  Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment , 2008, Apoptosis.

[9]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[11]  A. Asai,et al.  Caspase-9 Transduction Overrides the Resistance Mechanism against p53-mediated Apoptosis in U-87MG Glioma Cells , 2001, Neurosurgery.

[12]  L. Corcos,et al.  Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. , 2001, Cancer research.

[13]  Ronald Koschny,et al.  The promise of TRAIL—potential and risks of a novel anticancer therapy , 2007, Journal of Molecular Medicine.

[14]  E. Henson,et al.  The role of TRAIL death receptors in the treatment of hematological malignancies , 2008, Leukemia & lymphoma.

[15]  F. Kruyt.  TRAIL and cancer therapy. , 2008, Cancer letters.

[16]  R. K Srivastava.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer. , 2001, Neoplasia.

[17]  M. Israel,et al.  Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells. Commentaries , 2001 .

[18]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[19]  V. Catalano,et al.  Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer , 2008, Anti-cancer drugs.

[20]  W. El-Deiry,et al.  Death Domain Mutagenesis of KILLER/DR5 Reveals Residues Critical for Apoptotic Signaling* , 2001, The Journal of Biological Chemistry.

[21]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[22]  F. Khuri,et al.  Advances in Brief p 53 Upregulates Death Receptor 4 Expression through an Intronic p 53 Binding Site , 2004 .

[23]  Y. Yeh,et al.  Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells. , 1995, Life sciences.

[24]  D. Hershko,et al.  Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells , 2007, Anti-cancer drugs.

[25]  E. D. de Vries,et al.  The clinical trail of TRAIL. , 2006, European journal of cancer.

[26]  Yong J. Lee,et al.  Pretreatment of docetaxel enhances TRAIL‐mediated apoptosis in prostate cancer cells , 2008, Journal of cellular biochemistry.

[27]  J. Eberle,et al.  Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4 , 2007, Oncogene.

[28]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[29]  Emad S. Alnemri,et al.  Temperature-sensitive Differential Affinity of TRAIL for Its Receptors , 2000, The Journal of Biological Chemistry.

[30]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[31]  T. Burns,et al.  Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo , 2001, Oncogene.